You are here

Can Drug Companies Be Shamed Into Limiting Price Hikes?

Soaring drug prices and threats to 340B are big concerns for hospitals

The escalating cost of drugs and political threats to the federal 340B drug pricing program emerged as a common concern at the annual meeting of the American Hospital Association, held May 3–6 in Washington, D.C., according to a report posted on the Hospitals & Health Networks Daily website.

Safety net hospitals consider the 340B program “mission critical” and fervently hope the program does not fall victim to the intense lobbying now taking place by the pharmaceutical industry among federal and state lawmakers, the report says.

Representatives of Ascension Health echoed those sentiments in an interview with H&HN editor Bill Santamour between sessions at the AHA meeting.

“The loss of [340B] funding would be very dangerous,” said Peter M. Leibold, Ascension’s chief advocacy officer, noting that restricting the program would threaten access to medications and care for some of America’s neediest patients.

Mary Ella Payne, senior vice president of policy and system legislative leadership, said the organization has produced case studies of all Ascension hospitals participating in the 340B program to demonstrate its value and to be transparent about how the hospitals use the savings to enhance patient care. “We have an obligation to be transparent, and we are,” she said.

As an example of its value, Payne noted that the 340B program allows Ascension to provide chemotherapy infusions to rural cancer patients close to their homes, averting their need to travel long distances. Without 340B, that probably would not be viable.

The program has become even more essential as drug prices surge, advocates say. “Drug pricing increases have been enormous in the last year, and it’s really hurting,” Leibold said, pointing out that “these are everyday drugs, not just specialty drugs.”

Ascension’s size has not convinced pharmaceutical companies to hold back prices. “Here we are, the largest system in the country, and we can’t negotiate,” Payne said.

Recent reports in the Wall Street Journal, the New York Times, and elsewhere have drawn broad attention to the pricing issue. Governing magazine, in its May 6 online health report, noted, for instance, that the hepatitis C drug Sovaldi (sofosbuvir, Gilead Sciences) costs $1,000 per pill, amounting to $84,000 for a 12-week treatment, “which disproportionately plagues poor people on Medicaid.” Nearly every state has limited Medicaid patient access to Sovaldi to only the sickest.

Critics say most of the price increases appear to be arbitrary, and some have happened virtually overnight, even for medications that have been available for some time. They’re demanding more transparency from the drug industry. An editorial in the May 6 issue of the New York Times speculated that disclosures on investment and profit “might shame [drug] companies into restraining their price increases and provide state officials with information to determine what action to take.”

Legislation has been introduced in five states that would require manufacturers to file annual reports for their most expensive products that reveal all of their costs, from research to development to marketing, as well as profits and price increases, Governing reported. That’s something the pharmaceutical industry has lobbied hard against and, as Governing’s headline bluntly noted: “In state’s fight for price transparency, drugmakers are winning.”

Source: H&HN Daily; May 7, 2015.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress